Capecitabine improved relapse-free survival (hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.99; P=0.04) and was associated with significantly fewer adverse events than fluorouracil ...

A recent Cochrane review showed that combination regimens significantly improved tumor response and time to disease progression compared with single-agent chemotherapy, with a modest improvement in ...

Capecitabine (Xeloda, Hoffmann–La Roche), an oral prodrug of fluorouracil, has been shown to be efficacious as adjuvant chemotherapy in patients with gastrointestinal cancer. 5–7 However, its ...

The capecitabine and temozolomide arm showed double the grade 3-4 toxicity rates compared with the temozolomide arm (45% v 22%, OR [95% CI] = 2.69 [1.28 to 5.68]; Fisher's exact P = .005). Seven ...

Capecitabine is an oral fluoropyrimidine prodrug that is selectively converted within cancer cells to the active drug 5-fluorouracil. Clinical trials have indicated that capecitabine is a safe and ...

The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan ...

Capecitabine is a chemotherapy drug sold under the brand name Xeloda. It’s sometimes used as a treatment for gallbladder cancer.

For patients who received neratinib plus capecitabine, median OS was 21 months (95% CI, 17.7-23.8) compared with 18.7 months (95% CI, 15.5-21.2) for those who received lapatinib plus capecitabine ...

Around 300,000 people are treated with 5-FU or capecitabine in the United States each year, but its toxicity could well have prevented FDA approval were it up for approval today.

Capecitabine can induce sufficient hemolysis to cause an isolated rise in bilirubin levels (reported in 20–70% of patients), which can often lead to a degree of confusion over appropriate dose ...